loading
前日終値:
$12.58
開ける:
$12.53
24時間の取引高:
27,706
Relative Volume:
0.05
時価総額:
$771.52M
収益:
-
当期純損益:
$-153.16M
株価収益率:
-3.6499
EPS:
-3.37
ネットキャッシュフロー:
$-134.48M
1週間 パフォーマンス:
-19.08%
1か月 パフォーマンス:
-23.58%
6か月 パフォーマンス:
-46.55%
1年 パフォーマンス:
+43.12%
1日の値動き範囲:
Value
$12.32
$12.84
1週間の範囲:
Value
$12.32
$15.51
52週間の値動き範囲:
Value
$7.64
$30.19

Cullinan Therapeutics Inc Stock (CGEM) Company Profile

Name
名前
Cullinan Therapeutics Inc
Name
セクター
Healthcare (1195)
Name
電話
617-410-4650
Name
住所
ONE MAIN STREET, CAMBRIDGE
Name
職員
85
Name
Twitter
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
CGEM's Discussions on Twitter

CGEM を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
CGEM 12.33 771.52M 0 -153.16M -134.48M -3.37
VRTX 446.42 115.74B 10.63B -479.80M -1.35B 13.33
REGN 738.52 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 586.49 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.16 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.51 24.49B 3.30B -501.07M 1.03B 11.54

Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-05-01 開始されました Stifel Buy
2024-04-15 開始されました William Blair Outperform
2024-02-15 開始されました Wedbush Outperform
2023-06-15 開始されました TD Cowen Outperform
2022-11-21 開始されました BTIG Research Buy
2021-04-27 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-02-02 開始されました Evercore ISI Outperform
2021-02-02 開始されました Morgan Stanley Equal-Weight
2021-02-02 開始されました SVB Leerink Outperform
2021-02-01 開始されました H.C. Wainwright Buy
すべてを表示

Cullinan Therapeutics Inc (CGEM) 最新ニュース

pulisher
Nov 20, 2024

Cullinan Therapeutics Announces Q3 2024 Progress and Outlook - TipRanks

Nov 20, 2024
pulisher
Nov 20, 2024

What is Leerink Partnrs' Forecast for CGEM FY2025 Earnings? - MarketBeat

Nov 20, 2024
pulisher
Nov 15, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 6.3%Time to Sell? - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Blue Owl Capital Holdings LP Adjusts Stake in Cullinan Therapeutics Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Cullinan advances lupus treatment with new clinical trial By Investing.com - Investing.com Canada

Nov 14, 2024
pulisher
Nov 14, 2024

Cullinan advances lupus treatment with new clinical trial - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 - GlobeNewswire

Nov 14, 2024
pulisher
Nov 14, 2024

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager - The Bakersfield Californian

Nov 14, 2024
pulisher
Nov 14, 2024

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 - GlobeNewswire Inc.

Nov 14, 2024
pulisher
Nov 08, 2024

Cullinan Therapeutics' chief scientific officer sells $125,120 in stock By Investing.com - Investing.com Australia

Nov 08, 2024
pulisher
Nov 08, 2024

Cullinan Therapeutics' chief scientific officer sells $125,120 in stock - Investing.com India

Nov 08, 2024
pulisher
Nov 07, 2024

Cullinan Therapeutics: Q3 Earnings Snapshot - Darien Times

Nov 07, 2024
pulisher
Nov 07, 2024

Insider Sale: Chief Scientific Officer of Cullinan Therapeutics Inc (CGEM) Sells Shares - GuruFocus.com

Nov 07, 2024
pulisher
Nov 07, 2024

Cullinan Therapeutics Inc (CGEM) Quarterly 10-Q Report - Quartzy

Nov 07, 2024
pulisher
Nov 07, 2024

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 07, 2024
pulisher
Nov 07, 2024

Cullinan Therapeutics Advances Pipeline Despite $40.6M Loss; Maintains $639M Cash Position | CGEM Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 05, 2024

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Cullinan Therapeutics Inc - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

Cullinan Therapeutics to Present Preclinical Data for - GlobeNewswire

Nov 04, 2024
pulisher
Nov 04, 2024

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 - StockTitan

Nov 04, 2024
pulisher
Nov 03, 2024

Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $31.67 - MarketBeat

Nov 03, 2024
pulisher
Oct 30, 2024

FY2027 Earnings Forecast for CGEM Issued By Leerink Partnrs - MarketBeat

Oct 30, 2024
pulisher
Oct 24, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Receives New Coverage from Analysts at UBS Group - MarketBeat

Oct 24, 2024
pulisher
Oct 22, 2024

Exchange Traded Concepts LLC Sells 2,961 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Oct 22, 2024
pulisher
Oct 22, 2024

SG Americas Securities LLC Sells 70,115 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat

Oct 22, 2024
pulisher
Oct 22, 2024

Newco trend watch: Clusters of launches point to areas undergoing derisking - BioCentury

Oct 22, 2024
pulisher
Oct 20, 2024

cullinan oncology, inc. Earnings dates - RTTNews

Oct 20, 2024
pulisher
Oct 18, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 3.2%Here's Why - MarketBeat

Oct 18, 2024
pulisher
Oct 17, 2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Short Interest Update - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

Cullinan Oncology stock gets 5% price target increase, H.C. Wainwright remains bullish after FDA approval - Investing.com

Oct 17, 2024
pulisher
Oct 16, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Trading Up 7%Here's Why - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Cullinan Therapeutics' (CGEM) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Cullinan Therapeutics Gets FDA Approval for Lupus Treatment Study - Marketscreener.com

Oct 16, 2024
pulisher
Oct 16, 2024

Cullinan Therapeutics Receives U.S. FDA Clearance of - GlobeNewswire

Oct 16, 2024
pulisher
Oct 16, 2024

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus - StockTitan

Oct 16, 2024
pulisher
Oct 11, 2024

How did Cullinan Therapeutics Inc (CGEM) fare last session? - US Post News

Oct 11, 2024
pulisher
Oct 11, 2024

Cullinan Therapeutics Inc [CGEM] Records 200-Day SMA of $17.94 - Knox Daily

Oct 11, 2024
pulisher
Oct 09, 2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of "Buy" from Brokerages - MarketBeat

Oct 09, 2024
pulisher
Oct 06, 2024

Algert Global LLC Reduces Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat

Oct 06, 2024
pulisher
Oct 02, 2024

The Potential Rise in the Price of Cullinan Therapeutics Inc (CGEM) following insiders activity - Knox Daily

Oct 02, 2024
pulisher
Oct 02, 2024

Metric Deep Dive: Understanding Cullinan Therapeutics Inc (CGEM) Through its Ratios - The Dwinnex

Oct 02, 2024
pulisher
Oct 02, 2024

Results from Cullinan Therapeutics Inc (CGEM) show potential - US Post News

Oct 02, 2024
pulisher
Sep 30, 2024

Perceptive Advisors LLC Takes Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat

Sep 30, 2024
pulisher
Sep 28, 2024

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by Blue Owl Capital Holdings LP - MarketBeat

Sep 28, 2024
pulisher
Sep 27, 2024

Lynx1 Capital Management LP Buys New Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat

Sep 27, 2024
pulisher
Sep 26, 2024

There is no doubt that Cullinan Therapeutics Inc (CGEM) ticks all the boxes. - SETE News

Sep 26, 2024
pulisher
Sep 26, 2024

Deerfield Management Company L.P. Series C Increases Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat

Sep 26, 2024
pulisher
Sep 25, 2024

Cullinan Therapeutics Inc (CGEM)’s stock price in review: A technical analysis - US Post News

Sep 25, 2024
pulisher
Sep 24, 2024

Quarterly Metrics: Quick and Current Ratios for Cullinan Therapeutics Inc (CGEM) - The Dwinnex

Sep 24, 2024
pulisher
Sep 24, 2024

CGEM’s Debt-to-Equity Ratio at 0.00: What It Means for Cullinan Therapeutics Inc’s Future - The InvestChronicle

Sep 24, 2024
pulisher
Sep 24, 2024

Paradigm Capital Management Inc. NY Has $39.46 Million Stock Holdings in Concentrix Co. (NASDAQ:CNXC) - MarketBeat

Sep 24, 2024

Cullinan Therapeutics Inc (CGEM) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
大文字化:     |  ボリューム (24 時間):